Paul W. Hoelscher
Independent DirectorMr. Paul W. Hoelscher has been an Independent Director at Reneo Pharmaceuticals, Inc. (now OnKure Therapeutics, Inc.) since January 20, 2022. He joined Reneo Pharmaceuticals, Inc. in January 2022. He serves as Independent Director at Sagimet Biosciences Inc. since April 1, 2024. He was Chief Financial Officer and Executive Vice President at Horizon Pharmaceutical LLC since October 25, 2016 until May 2022. He serves as Vice Chair on the Board of trustees of the Illinois Region of The Leukemia and Lymphoma Society. Mr. Hoelscher had been the Chief Financial Officer and Executive Vice President of Horizon Therapeutics Public Limited Company (formerly known as Horizon Pharma plc) since October 01, 2014 until May 2022. He served as Executive Vice President of Finance at Horizon Therapeutics Public Limited Company (formerly known as Horizon Pharma plc) from June 23, 2014 to October 01, 2014. He joined Horizon from OfficeMax, Inc., where he served as Senior Vice President of Finance?treasury and corporate development from August 2013 to May 2014 and was co-lead in integration planning activities related to its recent merger with Office Depot. He was Vice President, finance?treasury and corporate development of OfficeMax, Inc from August 2012 to July 2013. Prior to that, he worked at Alberto Culver Company /Unilever and served as Vice President of Finance integration from May 2011 to May 2012 following Unilever?s acquisition of Alberto Culver. Previously, Mr. Hoelscher was Vice President, International Finance and Treasurer from 2010 to May 2011 and Vice President and Corporate Controller from 2004 to 2010. From 1993 to 2004, he served in other positions of increasing responsibility at Alberto Culver, including Manager, corporate accounting; Director, corporate finance; senior Director, corporate finance; and corporate Controller. Mr. Hoelscher has served on the Board of Trustees of the Illinois Chapter of The Leukemia and Lymphoma Society since 2007. Mr. Hoelscher also served in various positions in the audit practice at KPMG LLP from 1986 to 1993. During his time at Alberto Culver/Unilever from 1992 to 2012 and OfficeMax, he had broad responsibility for corporate accounting and reporting functions, financial planning and analysis, treasury, corporate development and Investor Relations, including significant international operations and mergers and acquisitions. He has been a Director at Horizon Pharmaceutical LLC since October 25, 2016. Mr. Hoelscher received his B.S. in Accountancy from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
Positions
- Company NameSagimet Biosciences Inc.Stock CodeSGMTPositionIndependent DirectorColleagues
- DADavid A. HappelCEO, President & Director
- GWGeorge W. KembleNon-Executive Chairman
- ERElizabeth RozekChief Legal & Administrative Officer
- UGUrs GreberCo-Founder
- LPLucas PelkmansCo-Founder
- TCThierry ChaucheCFO & Principal Accounting Officer
- BCBeth C. SeidenbergLead Independent Director
- EAElizabeth A. GrammerIndependent Director
